Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$1,145.03
-$5.16 (-0.4%)
Closing Price on September 20, 2024
REGN Articles
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Baidu, Barclays, Celgene, HPE, Intel, Kimberly-Clark, Lululemon, PayPal and Stratasys.
Published:
Last Updated:
24/7 Wall St. screened the Merrill Lynch US 1 list for the companies that have exhibited strong price momentum and found four that look like solid picks for the fourth quarter.
Published:
Last Updated:
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
Published:
Last Updated:
Investors often hear when to buy a stock, but rarely when to sell. So far in August at least 10 key Sell-equivalent analyst ratings have stood out.
Published:
Last Updated:
Stocks were indicated to open only slightly higher on Wednesday after a mixed bag of corporate earnings. What investors need to understand is that the major equity indexes remain just under all-time...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Carbonite, Coach, Credit Suisse, DaVita, Intuit, Pandora Media, ONEOK and Regeneron.
Published:
Last Updated:
Although Monday was an incredibly positive day for the markets, Tuesday was more or less a complete reversal. Practically every sector in the S&P 500 was down with the single exception of health...
Published:
Last Updated:
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls on Friday include Celgene, Continental Resources, Hess, Renewable Energy, U.S. Bancorp and Zynga.
Published:
Last Updated:
May 4, 2017: The S&P 500 closed slightly higher on the day, up 0.06% and 1.42 points to 2,389.55. Separately the DJIA closed down 0.03% on the day at 20,951.17, down approximately 6.73 points.
Published:
Last Updated:
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.
Published:
Last Updated:
One area is dirt cheap now, and in some cases pays dividends and has big growth prospects, and that is the large cap biotechs.
Published:
Last Updated: